Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

Moleculin

Hematology

Hematology Today—March 23, 2026

This week’s Hematology update highlights hemophilia gene therapy supply…

Hematology

Hematology Weekly News - September 22nd 2025

Hematology Update: Inobrodib Trial, Tecvayli Combo, Bexobrutideg Data and……

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Endocrinology Today—March 31, 2026
Obesity Today—March 31, 2026
Lucid Diligence Brief: Royalty Pharma and J&J partner in a $500M R&D deal for JNJ-4804
Hematology Today—March 30, 2026
Oncology Today—March 30, 2026

Tags

Acute Coronary Syndrome Chronic disease mortality conduction-system pacing consumer triage AI cost reduction Cytarabine DIPS Arena Dizal Pharmaceutical endocrine therapy Enfortumab Vedotin Enzalutamide FDA Digital Health Advisory FG001 GLP-1 Receptor Agonists gout flares IMAAVY immunohistochemistry Jaypirca Linerixibat live biotherapeutic product LIVMARLI LUMEVOQ MicroRNAs naxtarubicin OCALIVA PPMS provider strategy Rapport Therapeutics RCT-Twin-GAN REM-422 Rinvoq Rituximab ROS1-Positive Non-Small Cell Lung Cancer Scandinavian Biopharma Spikevax Stanford Medicine Sutra Medical SVT-001 TG Therapeutics Tivdak TLX591-Tx Transgene Ver-A-T1D Voro Therapeutics Zydus

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Endocrinology Today—March 31, 2026
Obesity Today—March 31, 2026
Lucid Diligence Brief: Royalty Pharma and J&J partner in a $500M R&D deal for JNJ-4804
Hematology Today—March 30, 2026
Oncology Today—March 30, 2026

TAGS

Acute Coronary Syndrome Chronic disease mortality conduction-system pacing consumer triage AI cost reduction Cytarabine DIPS Arena Dizal Pharmaceutical endocrine therapy Enfortumab Vedotin Enzalutamide FDA Digital Health Advisory FG001 GLP-1 Receptor Agonists gout flares IMAAVY immunohistochemistry Jaypirca Linerixibat live biotherapeutic product LIVMARLI LUMEVOQ MicroRNAs naxtarubicin OCALIVA PPMS provider strategy Rapport Therapeutics RCT-Twin-GAN REM-422 Rinvoq Rituximab ROS1-Positive Non-Small Cell Lung Cancer Scandinavian Biopharma Spikevax Stanford Medicine Sutra Medical SVT-001 TG Therapeutics Tivdak TLX591-Tx Transgene Ver-A-T1D Voro Therapeutics Zydus

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy